News

A survey of beliefs about Alzheimer’s disease dementia identified the stigmas that pose a hurdle to clinical trials for therapies.

When a physician becomes famous, opportunities abound. How can they ensure they’re leveraging the limelight responsibly?

Many physicians suggest upping a child’s dose of inhaled corticosteroids at the first symptoms of an asthma flare-up, but more research suggests the increased dosage makes no difference.

This reduction has the potential to significantly increase HIV transmission at the community level.

The Beyond Type 1 Science Advisory Council member explains the warning signs of diabetes.

FDA Commissioner, Scott Gottlieb, MD released a statement this morning, stressing the FDA’s intention to incorporate the patient experience into the regulatory authority’s benefit-risk assessments.

Results from a recent study found that the mutated huntingtin gene in patients with HD generates a class of small molecules that are highly toxic to cancer cells, but not healthy cells.

The association between long-term antibiotic use and death is especially noticeable while looking at death from heart disease.

A study published in the journal eLife suggests that blocking an enzyme could reduce levels of the mutant huntingtin (mHTT) protein.

The placebo-controlled study found that the supplement reduced physiological as well as psychological symptoms of PMS.

Science has begun to lean on P values as the gold standard for study results, which has led to the misconception that statistical significance equals truth.

Lower respiratory infections account for 78.8% of all infectious disease-related deaths, while also reporting the widest absolute mortality inequality among US counties.

Insmed Incorporated announced that it has submitted its New Drug Application for amikacin liposome inhalation suspension (ALIS) to the U.S. FDA.

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to blinatumomab (Blincyto) for the treatment of adults and children with B-cell precursor ALL who are in remission, but still have minimal residual disease.

In the ATTR-ACT study, tafamidis exhibited a statistically significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations in transthyretin cardiomyopathy patients.

Catalyst Pharmaceuticals announces its submission of an NDA to the FDA for amifampridine phosphate (Firdapse) for the treatment of LEMS.

Doctors of osteopathic medicine have long sought to be viewed equally in the eyes of their colleagues, but their differences may have helped shape modern medicine. Does stigma still exist?

A CDC analysis found that overall drug overdose death rates increased by 21.5%, but those involving synthetic opioids more than doubled.

A new study concludes that, among patients with AML, the detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates.

The FDA granted orphan drug designation to Scholar Rock for its lead antibody product candidate, SRK-015, for the treatment of spinal muscular strophy (SMA).

Clinical data from an ongoing Phase 2 study of PBI-4050 shows that the drug provides a clear clinical benefit in patients with Alstrom syndrome.

Depressive mood and irritability in childhood was found to double the likelihood of suicidality in adolescence.

Analysis including 2,848,768 deaths since 1980 has revealed increases in mortality rates due to drug abuse disorders, as well as increases in rates for self-harm and alcohol use disorders since 2000.

A joint effort must be made to include PLWH from these at-risk groups in observational and interventional studies to understand stroke mechanisms and reducing stroke risk in HIV infection.

Phase 3 of the NEWTON 2 study of EG-1962 in aSAH has been terminated since it is unlikely to meet its primary endpoint.

The FDA granted Cynata’s Therapuetics Limited (ASX:CYP) orphan-drug designation for CYP-001, which is the company’s potential treatment for acute graft versus host disease (GvHD).

Results from a trial sponsored by the National Cancer Institute demonstrate that sorafenib tosylate (Nexavar) extended progression-free survival in patients with desmoid tumors or aggressive fibromatosis.

The FDA granted GeneTx Biotherapeutics LLC orphan-drug designation for GTX-101, the company’s potential treatment for Angelman syndrome.

At the 16th International Symposium on Amyloidosis, Alnylam presented results from the APOLLO Phase 3 study of patisiran, which targets transthyretin in hATTR amyloidosis.

The success of VNS during post-stroke rehab has led to the enrolling of a clinical trial to test the therapy in patients who have experienced a stroke.